Sangamo BioSciences Reports Third Quarter 2008 Financi...(ter study designed to evaluate the...)

evaluate the effect of intramuscular administration of SB-509 on the

progression of the disease in subjects with ALS. In addition to

gathering data on safety and tolerability of SB-509, the study will

also evaluate stem cell mobilization in subjects with ALS receiving

SB-509.

* Presentation of additional data from Phase 1b study of SB-509

(SB-509-401) and interim data from Phase 2 study (SB-509-701) in

subjects with diabetic neuropathy (DN). Additional data from the

Phase 1b clinical trial (SB-509-401) were presented at the 44th Annual

Meeting of the European Association for the Study of Diabetes (EASD),

demonstrating a statistically significant (p=0.0016) positive

correlation of 2 or more response endpoints in the SB-509 treated group

compared with placebo treated subjects at day 180 post-treatment.

Response endpoints were defined as greater than a 14% improvement in

quantitative sensory testing (QST), greater than 0.8 meters/second

(m/sec) improvement in NCV and greater than a 3 point improvement as

judged by the Neuropathy Impairment Scale - Lower Limbs (NIS-LL). The

trial was conducted in subjects with mild to moderate diabetic

neuropathy over a six month period after a single administration of

SB-509. Positive interim clinical data were also presented at the

International Society for Cellular Therapy (ISCT) Europe Regional

Meeting in Antwerp, Belgium from the Phase 2 trial of SB-509

(SB-509-701) conducted in subjects with moderate to severe DN who

entered the trial with at least one "blocked nerve". The data

demonstrate recovery of sensory nerve conduction velocity (NCV) in 75%

of SB-509 treated subjects compared to 25% of placebo treated subjects.

SB-509 is an injectable formulation of plasmid DNA tha
'/>"/>